Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-01-09
2000-09-19
LeGuyader, John L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
4241341, 4241581, 530300, 530350, 5303871, A61K 3817, A61K 39395
Patent
active
06121230&
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to the discovery of expression of vascular endothelial growth factor (VEGF) and its associated receptors (Flt and KDR) in certain tissues and as a consequence demonstrates the potential for VEGF antagonists in the treatment/prevention of endometriosis and related conditions.
BACKGROUND OF THE INVENTION
Endometriosis is defined as the presence of endometrial cells outside of the uterine cavity. The disease affects women during their childbearing years with deleterious social, sexual and reproductive consequences. The development and maintenance of endometriosis involves the establishment and subsequent sustained growth of endometrial cells at ectopic sites, most commonly the pelvic peritoneum, following retrograde menstruation (Sampson 1927 Am. J. Obstet. Gynecol. 14, 422; Ridley & Edward 1958 Am. J. Obstet. Gynecol. 76, 783-790; Lieu & Hitchcock 1968 Br. J. Obstet. Gynecol. 93, 859-862; and Thomas & Prentice 1992 Repro. Med. Rev. 1, 21-36). Except for the influences of ovarian steroid hormones (Dizerega et al., 1980 Fertil. Steril. 33, 649-653; Bergqvist et al., 1985 Am. J. Pathol. 121, 337-341) little is known about the factors that control this disease. However, it may be that the growth of ectopic endometrial implants is influenced by angiogenic growth factors (angiogenesis being the name given to the formation of new blood vessels).
Endometriotic lesions are characterised by hyper-vascularisation both within the endometriotic tissue and in the surrounding peritoneum (Shaw, p46-47 "An atlas of endometriosis" 1993, The Parthenon publishing group; and Folkman & Shing 1992 J. Biol. Chem. 267, 10931-10934). Vascular endothelial growth factor (VEGF) is a recently characterised angiogenic protein being a potent mitogen for endothelial cells and a mediator of vessel permeability (Ferrara et al., 1992 Endocrinol. Rev. 13, 18-32). VEGF and its receptors flt and KDR, which are expressed on endothelial cells, (De Vries et al., 1992 Science 255, 989-991) have been implicated in angiogenesis in the developing embryo (Breier et al., 1992 Development 114, 521-532; Jakeman et al., 1993 Endocrinology 133, 848-859; and Millauer et al., 1993 Cell 72, 835-846) and in adult tissue undergoing profound angiogenesis such as eutopic endometrium (Chamock-Jones et al., 1993 Biol. Repro. 48, 1120-1128) and the lutenised corpus luteum (Ravindranath et al., 1992 Endocrinology 13, 254-260). In addition, its role in tumour angiogenesis is becoming well established (Shweiki et al., 1992 Nature 359, 843-848; Kim et al., 1993 Nature 362, 841-844).
The present inventors sought to determine whether VEGF and its associated receptor flt are present in endometrial tissue. In addition, they sought to determine whether other cells such as the peritoneal macrophages, whose numbers and activation status are known to be elevated in this disease (Halme et al., 1983 Am. J. Obstet. Gynecol. 145, 333-337; Olive et al., 1985 Fertil. Steril. 44, 772-777; and Halme et al., 1987 Am. J. Obstet. Gynecol. 156, 783-789), may also be involved in the pathogenesis of endometriosis through the secretion of VEGF.
SUMMARY OF THE INVENTION
In a first aspect the invention provides a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance.
It will be apparent that there are many possible agents for use in compositions in accordance with the invention, which could vary considerably in their nature, depending on the mode of action of the selected agent.
For example, agents could be used to block VEGF production systematically or, preferably, locally (i.e. in or around the endometriotic tissue). Desirably, one might use an agent to block VEGF production by local macrophages, which seems to play a particularly important role in pathogenesis. It has been shown that VEGF expression may be regulated by steroids (e.g. Charnock-Jones et al., 1993 Biology of Reproduction 48, 1120-1128), and
REFERENCES:
Society for the study of Reproduction, Biology of Reproduction vol. 58, Suppl. 1, p213, Abstract #:454, 1998.
Osteen et al., Seminars in Reproductive Endoinology 14(3):247-255, Aug. 1996.
Burner et al. Metalloproteinases and Experimental Edometriosis vol. 99 (12), pp. 2851-2857, Jun. 1997.
Stall et al. Pharm. Res. 12:465-483 (1995).
Gewirtz et al PNAS 93:3161-3163 (1996).
Rojanasakul Advanced Drug Del. Reviews 18:115-131 (1996).
Charnock-Jones David Stephen
McLaren John
Prentice Andrew
Smith Stephen Kevin
LeGuyader John L.
Metris Therapeutics Limited
LandOfFree
Anti-VEGF agents in the treatment of endometriosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-VEGF agents in the treatment of endometriosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-VEGF agents in the treatment of endometriosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073249